@phdthesis{MuellerBotz2010, author = {M{\"u}ller-Botz, Stephan}, title = {Mechanismus der schnellen Geninduktion von Egr-1 durch {\"O}strogen am Herzen : Ein Steroidhormon geht neue Wege}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-51730}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2010}, abstract = {{\"O}strogen bewirkt in physiologischer Konzentration in Kardiomyozyten eine schnelle Induktion des Egr-1-Promotors. Dieser Effekt wird {\"u}ber die {\"O}strogenrezeptoren ER alpha und ER beta vermittelt. {\"U}berraschenderweise erfolgt die {\"o}strogenabh{\"a}ngige Genregulation von Egr-1 aber nicht {\"u}ber den klassischen Signalweg mittels Bindung des {\"O}strogenrezeptors an {\"o}strogenresponsive Elemente (ERE), sondern findet unter Bindung von Serumfaktor an serumresponsive Elemente (SRE) des Egr-1-Promotors unter Mitbeteiligung des ERK1/2-Signalweges statt. Am Beispiel der Egr-1-Induktion durch {\"O}strogen ließ sich die Bedeutung serumresponsiver Elemente (SRE) f{\"u}r die Genregulation durch {\"O}strogen aufzeigen. In der vorliegenden Arbeit konnte damit ein neuartiger Signalweg bei der {\"o}strogenabh{\"a}ngigen schnellen Genaktivierung in Kardiomyozyten gezeigt werden.}, subject = {{\"O}strogene}, language = {de} } @phdthesis{Pickel2020, author = {Pickel, Simone}, title = {Role of the β subunit of L-type calcium channels in cardiac hypertrophy}, doi = {10.25972/OPUS-19282}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-192829}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2020}, abstract = {L-type calcium channels (LTCCs) control crucial physiological processes in cardiomyocytes such as the duration and amplitude of action potentials, excitation-contraction coupling and gene expression, by regulating the entry of Ca2+ into the cells. Cardiac LTCCs consist of one pore-forming α1 subunit and the accessory subunits Cavβ, Cavα2δ and Cavγ. Of these auxiliary subunits, Cavβ is the most important regulator of the channel activity; however, it can also have LTCC-independent cellular regulatory functions. Therefore, changes in the expression of Cavβ can lead not only to a dysregulation of LTCC activity, but also to changes in other cellular functions. Cardiac hypertrophy is one of the most relevant risk factors for congestive heart failure and depends on the activation of calcium-dependent prohypertrophic signaling pathways. However, the role of LTCCs and especially Cavβ in this pathology is controversial and needs to be further elucidated. Of the four Cavβ isoforms, Cavβ2 is the predominant one in cardiomyocytes. Moreover, there are five different splice variants of Cavβ2 (Cavβ2a-e), differing only in the N-terminal region. We reported that Cavβ2b is the predominant variant expressed in the heart. We also revealed that a pool of Cavβ2 is targeted to the nucleus in cardiomyocytes. The expression of the nuclear Cavβ2 decreases during in vitro and in vivo induction of cardiomyocyte hypertrophy and overexpression of a nucleus-targeted Cavβ2 completely abolishes the in vitro induced hypertrophy. Additionally, we demonstrated by shRNA-mediated protein knockdown that downregulation of Cavβ2 enhances the hypertrophy induced by the α1-adrenergic agonist phenylephrine (PE) without involvement of LTCC activity. These results suggest that Cavβ2 can regulate cardiac hypertrophy through LTCC-independent pathways. To further validate the role of the nuclear Cavβ2, we performed quantitative proteome analyses of Cavβ2-deficient neonatal rat cardiomyocytes (NRCs). The results show that downregulation of Cavβ2 influences the expression of various proteins, including a decrease of calpastatin, an inhibitor of the calcium-dependent cysteine protease calpain. Moreover, downregulation of Cavβ2 during cardiomyocyte hypertrophy drastically increases calpain activity as compared to controls after treatment with PE. Finally, the inhibition of calpain by calpeptin abolishes the increase in PE-induced hypertrophy in Cavβ2-deficient cells. These results suggest that nuclear Cavβ2 has Ca2+- and LTCC-independent functions during the development of hypertrophy. Overall, our results indicate a new role for Cavβ2 in antihypertrophic signaling in cardiac hypertrophy.}, subject = {Herzhypertrophie}, language = {en} }